Freimooser Sina, Traidl Stephan, Werfel Thomas
Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Dermatologie (Heidelb). 2022 Jul;73(7):514-519. doi: 10.1007/s00105-022-05005-5. Epub 2022 May 19.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. In everyday clinical practice, about 80% of patients present with mild to moderate disease, which is usually treated with topical therapy. Topical anti-inflammatory therapy thus continues to be the standard of care in addition to the basic therapy. Topical glucocorticoids (TGC) and topical calcineurin inhibitors (TCI) are two potent approved substances that are available. In addition to newly developed systemic therapies for moderate to severe AD, there are also new therapeutic approaches in anti-inflammatory topical treatment. Topical Janus kinase inhibitors show a high therapeutic effect. However, only delgocitinib and ruxolitinib have so far been approved for topical administration in Japan and the USA since 2021. Crisaborole, a phosphodiesterase 4 inhibitor, also received approval in the USA. Other phosphodiesterase inhibitors are currently being investigated in clinical trials. Interesting results of clinical studies give hope for further substances and therapeutic approaches.
特应性皮炎（AD）是最常见的慢性炎症性皮肤病之一。在日常临床实践中，约80%的患者表现为轻至中度疾病，通常采用局部治疗。因此，除基础治疗外，局部抗炎治疗仍是标准治疗方法。局部糖皮质激素（TGC）和局部钙调神经磷酸酶抑制剂（TCI）是两种有效的已获批药物。除了新开发的用于中重度AD的全身治疗方法外，抗炎局部治疗也有新的治疗方法。局部Janus激酶抑制剂显示出很高的治疗效果。然而，到目前为止，自2021年以来，只有地尔戈替尼和芦可替尼在日本和美国获批用于局部给药。磷酸二酯酶4抑制剂克立硼罗也在美国获得批准。其他磷酸二酯酶抑制剂目前正在临床试验中进行研究。临床研究的有趣结果为进一步的药物和治疗方法带来了希望。
